Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical-stage gene editing company headquartered in Durham, North Carolina, United States. Founded in 2006, the company is dedicated to improving life through its novel and proprietary ARCUS® genome editing platform, focusing on developing therapies for high unmet medical needs, including genetic and infectious diseases.

The company's core technology is the ARCUS genome editing platform, which utilizes sequence-specific DNA-cutting enzymes (nucleases) to precisely insert, remove, or repair DNA within living cells and tissues. Precision BioSciences is developing in vivo gene editing therapies for various conditions, including genetic disorders like Duchenne muscular dystrophy (DMD) and infectious diseases such as Hepatitis B (HBV). Key programs in their pipeline, PBGENE-HBV and PBGENE-DMD, are currently in clinical trials.

Michael Amoroso serves as the President and CEO, having been appointed in October 2021. As of late April 2026, Precision BioSciences is actively advancing its pipeline, with recent announcements including the activation of the first clinical trial site and patient enrollment for its Phase 1/2 FUNCTION-DMD study for Duchenne Muscular Dystrophy. The company is also expanding its ELIMINATE-B trial for chronic Hepatitis B in Europe and presented late-breaking data for PBGENE-HBV at the European Association for the Study of the Liver (EASL) Congress 2026.